Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
cbdMD, Inc is a business based in the US. cbdMD shares (YCBD-PA) are listed on the NYSE and all prices are listed in US Dollars. cbdMD employs 165 staff and has a trailing 12-month revenue of around USD$44.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$3.8564 - USD$11 |
---|---|
50-day moving average | USD$8.313 |
200-day moving average | USD$8.3349 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A (7.62%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$44.1 million |
---|---|
Gross profit TTM | USD$26.4 million |
Return on assets TTM | -6.83% |
Return on equity TTM | -13.76% |
Profit margin | -22.07% |
Book value | N/A |
Market capitalisation | USD$0 |
TTM: trailing 12 months
Dividend payout ratio: 92% of net profits
Recently cbdMD has paid out, on average, around 92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 7.62% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), cbdMD shareholders could enjoy a 7.62% return on their shares, in the form of dividend payments. In cbdMD's case, that would currently equate to about $N/A per share.
cbdMD's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
cbdMD's most recent dividend payout was on 15 March 2021.
Over the last 12 months, cbdMD's shares have ranged in value from as little as $3.8564 up to $11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while cbdMD's is 1.7885. This would suggest that cbdMD's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.